Kristel Gonzalez

Hoy ingresaron a mi domicilio con violencia. Desde Mayo/2020 tengo #amenazas de muerte. Ya había denunciado ante la @FGR_Tamps sede #NuevoLaredo y @FGJ_Tam . Mi vida y la de mi familia siguen en riesgo. @CEAVmex @CNDH @inmujeres @CONAVIM_MX @Carmenliliacrv #Tamaulipas

#ESMO25 abstract decisions have started to be announced. Check your email👇 @myESMO

Estimados todos, les mando saludos cordiales y les recuerdo nuestra próxima sesión del miércoles 20.00hrs.Bolivia, es ya la que corresponde a la clausura. ⁦@SLAPpatologia⁩

Senseless bureaucracy from a friend. Respiratory fit test (“protects”from respiratory illnesses like TB) mandatory for physicians by end July (together with 30 minute course) . But also repeated in birth month, which is September for colleague. Rules are rules @HemeAaron42296

Completely agree, & c/w "#Universal #Germline #GeneticTesting for Hereditary #Cancer Syndromes in #Patients With Solid Tumor Cancer" ascopubs.org/doi/10.1200/PO… @JCOPO_ASCO #access #reducedisparities #precisionmedicine #precisiontherapy #clinicaltrials #precisionprevention

Hola a todos. Les dejo la información de la sesión SLAP del próximo miércoles 9 de julio, nos vemos pronto.⁦@SLAPpatologia⁩

Every cancer patient deserves a complete diagnosis.

First evidence that AGBL5 variants cause retinitis pigmentosa with hearing loss, suggesting a syndromic form. nature.com/articles/s4143…

Read a summary of "Guidelines for performing ultrasound-guided vascular cannulation: Recommendations of the American Society of Echocardiography," in the June 2025 Science, Medicine, and the Anesthesiologist: ow.ly/Rn8F50Wjh2a

Every cancer patient deserves a diagnosis Providing links. as requested. 2016 AMA journal paper: pubmed.ncbi.nlm.nih.gov/27078832/ 2023 ASCO journal paper pubmed.ncbi.nlm.nih.gov/36930859/ @VivekSubbiah

Today, FDA provided important updates on the risk of myocarditis after receiving an mRNA COVID-19 vaccine, noting the risk is higher in young men.

The Somatic Mosaicism across Human Tissues Network | Nature nature.com/articles/s4158…

Wonderful time, beautiful place but above all, extraordinary people !!! 🙂

Dr Grewal did a wonderful job going ver this critical new target MUC1/CA27.29;CA15.3 nature.com/articles/s4169…

We will never stop trying/ Nunca dejaremos de intentarlo.

¿Quieres actualizarte con lo último de melanoma? Escúchame en @sciencelinkonco y Spotify

Proud of the fact that we have avoided a ‘manel’. Nearly one third of our speakers are women. @cspramesh

Don’t miss Session 3 at #APGCS2025: Hepatobiliary Malignancies. Debates, fireside chats & key updates on HCC & BTC treatment—incl. Y90 therapy, SIERRA & TOURMALINE trials. 📅 Aug 1–2 | Singapore 🔗 Register now: apgcs.com/register-for-a… #GIOncology #LiverCancer

✨ Relacorilant + Nab‑Paclitaxel: A New Standard in Platinum‑Resistant OC! ✨ 🎯 Objective: Boost survival in platinum‑resistant epithelial ovarian cancer by combining the selective glucocorticoid receptor antagonist relacorilant with weekly nab‑paclitaxel (ROSELLA, phase III). ✅ Inclusion Criteria: - Adults with platinum‑resistant ovarian, peritoneal, or fallopian tube carcinoma - ECOG 0–1, measurable disease, progression <6 months post‑platinum - Prior taxanes, bevacizumab, and ≤3 systemic treatments 📊 Key Results: 1️⃣ Median PFS improved to 6.5 vs 5.5 months (HR 0.70; p=0.0076) via blinded review 2️⃣ Median OS increased to 16.0 vs 11.5 months (HR 0.69; p=0.0121) 3️⃣ At 12 months, survival was 60% vs 49%; objective response rate ~36.9% vs 30.1% 4️⃣ Safety Profile: Manageable despite more grade ≥3 AEs (74.5% vs 59.5%), similar when adjusted for exposure time. 🧠 Conclusion: This landmark phase III trial establishes relacorilant + nab‑paclitaxel as a promising new option, significantly improving PFS and OS in a hard‑to‑treat group. Safety is acceptable for widespread use. #OvarianCancer #ROSELLA #Relacorilant #NabPaclitaxel #GynecologicOncology #CancerBreakthrough 💊🎯🙌 @ASCO @myESMO @OncoAlert @AndreaAnampaG @IshwariaMD @neerajaiims @tmprowell @UmbertoMalapel1 @SewantiLimaye @AnaVManana @Kristel_GT @NazliDizman @katsuki_arima @VJOncology @DarcyBurbage

✨ First FDA-Approved PD‑1 Combo for Anal Cancer! ✨📰 🎯 Objective: Assess efficacy of retifanlimab‑dlwr (Zynyz®) with carboplatin + paclitaxel (1L) and as monotherapy (2L+) in locally recurrent/metastatic SCAC. ✅ Inclusion Criteria: • Adults with inoperable locally recurrent or metastatic SCAC • Chemo-naïve for combination arm; prior platinum exposure for monotherapy arm 📊 Key Findings: 1️⃣ Combo arm (POD1UM‑303): PFS improved to 9.3 mo vs 7.4 mo (HR 0.63; p=0.0006) 2️⃣ ORR: 56% with combo vs 44% without DOR ~14 mo vs ~7.2 mo 3️⃣ Monotherapy (POD1UM‑202): ORR 14%, median DOR 9.5 mo 4️⃣ Safety: No new signals; serious AEs reported in ~47% of combo patients 🧠 Conclusion: Retifanlimab‑dlwr combo sets a new standard first-line therapy for advanced SCAC, with strong PFS/response benefits. Monotherapy offers a new option for platinum-refractory patients. #AnalCancer #Retifanlimab #PD1 #Immunotherapy #SCAC #OncologyBreakthrough 💉🧬🚀 @UmbertoMalapel1 @SewantiLimaye @AnaVManana @Kristel_GT @NazliDizman @katsuki_arima @VJOncology @DarcyBurbage @manjuggm @MHuynhLe @EileenMOReilly @DenboJw @NiuSanford @YJanjigianMD @JTrentMDPhD @GIcancerDoc

La biopsia líquida es y será sumamente necesaria para monitorizar eficacia y resistencias a los tratamientos oncológicos.